May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
The Effect of Combinations of Flurbiprofen, Low Molecular Weight Heparin, and Doxycycline on the Inhibition of Corneal Neovascularization
Author Affiliations & Notes
  • A.A. Kazi
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
    Ophthalmology, Isra University, Hyderabad, Pakistan
  • G.A. Peyman
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
  • M.R. Esfahani
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
    Ophthalmology, Tehran University Eye Research Center, Tehran, Iran (Islamic Republic of)
  • E. Aydin
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
    Ophthalmology, Gaziosmanpasa University, Tokat, Turkey
  • M. Kivilcim
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
  • D.R. Sanders
    Ophthalmology, University of Illinois College of Medicine, Chicago, IL
  • Footnotes
    Commercial Relationships  A.A. Kazi, None; G.A. Peyman, None; M.R. Esfahani, None; E. Aydin, None; M. Kivilcim, None; D.R. Sanders, Regenera Limited I, C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4478. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A.A. Kazi, G.A. Peyman, M.R. Esfahani, E. Aydin, M. Kivilcim, D.R. Sanders; The Effect of Combinations of Flurbiprofen, Low Molecular Weight Heparin, and Doxycycline on the Inhibition of Corneal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4478.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the effect of various combinations of flurbiprofen, low molecular weight heparin (LMWH), and doxycycline on the inhibition of corneal neovascularization in rats. Methods: Chemical cauterization of the cornea in 32 eyes of 32 rats was performed by using silver nitrate/potassium nitrate sticks. The rats were anesthetized and were treated in accordance with the ARVO statement on the use of animals in ophthalmic and visual research. The animals were divided into 4 groups. Topical instillation of 0.015% flurbiprofen with 5 mg/ml LMWH, flurbiprofen with 10 mg/ml doxycycline, doxycycline with LMWH, and saline was performed twice a day for 7 days in the respective groups. Slit–lamp photography was performed to determine the percent area of cornea covered by neovascularization and also covered by scar in each group. The means of different groups were compared to find any significant (p < 0.05) difference with the control and any difference between the groups. At the end of the experiment, the animals were euthanized and the eyes were enucleated for evaluation by light microscopy. Results: The means of percent area of corneal neovascularization of the different groups were: in flurbiprofen with doxycycline, 6.6 ± 5.5; in LMWH with doxycycline, 22.0 ± 27.6; in flurbiprofen with LMWH, 48.5 ± 13.1; and in saline, 64.6 ± 9.9. The means of percent area of neovascularization in the flurbiprofen with doxycycline group and doxycycline with LMWH group were significantly lower compared to the control and the flurbiprofen with LMWH groups. There was no significant difference in the percent corneal neovascularization between the flurbiprofen with doxycycline group and the doxycycline with LMWH groups. Similarly, there was no significant difference between the flurbiprofen with LMWH and control groups. Histology was consistent with our slit–lamp evaluations. Conclusions: Topical instillation of combinations of doxycycline with either flurbiprofen or LMWH can effectively inhibit corneal neovascularization induced by chemical cauterization of the cornea in rats.

Keywords: neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×